Moreover, immunoblotting analysis of the p53 signaling pathway proved that PMIBcr/Abl‐R6 efficiently activated the p53 pathway in this imatinib‐resistant ALL cell line (Figure 5B). Here, TP53 is linked to acute lymphoblastic leukemia.